BIAFW (bioAffinity Technologies, Inc. Warrant)
Insider Trading Activity
Every open-market purchase and sale reported by BIAFW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-14 | Maria Zannes | President & CEO | A | — | — |
| 2025-01-14 | James Michael Edwards | VP and CFO | A | — | — |
| 2025-01-14 | STEVEN GIRGENTI | Executive Chairman | A | — | — |
| 2025-01-14 | Xavier Trinidad Reveles | Chief Operating Officer | A | — | — |
| 2025-01-14 | Timothy P Zannes | Secretary, EVP, Gen. Counsel | A | — | — |
| 2024-11-05 | James Michael Edwards | VP and CFO | A | — | — |
| 2024-07-02 | STUART DIAMOND | Director | A | — | — |
| 2024-07-02 | STEVEN GIRGENTI | Executive Chairman | A | — | — |
| 2024-07-02 | Jamie Platt | Director | A | — | — |
| 2024-07-02 | Robert A. Anderson | Director | A | — | — |
| 2024-07-02 | PETER S KNIGHT | Director | A | — | — |
| 2024-07-02 | Maria Zannes | President & CEO | A | — | — |
| 2024-07-02 | Roby Joyce | Director | A | — | — |
| 2024-07-02 | Harvey Sandler Revocable Trust | 10%+ Owner | A | — | — |
| 2024-06-14 | PETER S KNIGHT | Director | A | — | — |
| 2024-06-14 | Maria Zannes | President & CEO | A | — | — |
| 2024-06-14 | STUART DIAMOND | Director | A | — | — |
| 2024-06-14 | Jamie Platt | Director | A | — | — |
| 2024-06-14 | Robert A. Anderson | Director | A | — | — |
| 2024-06-14 | Roby Joyce | Director | A | — | — |
| 2024-06-14 | Gary D Rubin | Director | A | — | — |
| 2024-06-14 | STEVEN GIRGENTI | Executive Chairman | A | — | — |
| 2024-04-24 | Timothy P Zannes | Secretary, EVP, Gen. Counsel | MIXED | — | — |
| 2024-04-24 | STEVEN GIRGENTI | Director | MIXED | — | — |
| 2024-04-24 | Maria Zannes | President & CEO | MIXED | — | — |
| 2024-03-29 | Robert A. Anderson | Director | M | — | — |
| 2024-03-29 | STEVEN GIRGENTI | Executive Chairman | A | — | — |
| 2024-02-02 | Timothy P Zannes | Secretary, EVP, Gen. Counsel | A | — | — |
| 2024-02-02 | Xavier Trinidad Reveles | Chief Operating Officer | A | — | — |
| 2024-02-02 | Michael Philip Dougherty | Chief Financial Officer | A | — | — |
| 2024-02-02 | STEVEN GIRGENTI | Executive Chairman | A | — | — |
| 2024-02-02 | Vivienne I Rebel | Chief Sci. & Med. Officer, EVP | A | — | — |
| 2024-02-02 | Maria Zannes | President, CEO | A | — | — |
| 2024-01-24 | Mohsin Y Meghji | Director | A | — | — |
| 2024-01-24 | PETER S KNIGHT | Director | A | — | — |
| 2024-01-24 | Robert A. Anderson | Director | A | — | — |
| 2024-01-24 | Maria Zannes | President, CEO | A | — | — |
| 2024-01-24 | Gary D Rubin | Director | A | — | — |
| 2024-01-24 | Jamie Platt | Director | A | — | — |
| 2024-01-24 | Joyce Living Trust | — | A | — | — |
| 2024-01-24 | STUART DIAMOND | Director | A | — | — |
| 2024-01-24 | STEVEN GIRGENTI | Executive Chairman | A | — | — |
| 2023-08-11 | STEVEN GIRGENTI | Executive Chairman | A | — | — |
| 2023-07-06 | Robert A. Anderson | Director | A | — | — |
| 2023-07-06 | Maria Zannes | President, CEO | A | — | — |
| 2023-07-06 | Michael Philip Dougherty | Chief Financial Officer | A | — | — |
| 2023-07-06 | PETER S KNIGHT | Director | A | — | — |
| 2023-07-06 | Mohsin Y Meghji | Director | A | — | — |
| 2023-07-06 | Gary D Rubin | Director | A | — | — |
| 2023-07-06 | STUART DIAMOND | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,730,741 | — |
| — | Director | 1,696,957 | — |
| — | Executive Chairman | 1,089,017 | — |
| — | Director | 649,745 | — |
| — | — | 594,997 | — |
| — | 10%+ Owner | 313,098 | — |
| — | President & CEO | 280,359 | — |
| — | Director | 163,936 | — |
| — | VP and CFO | 120,128 | — |
| — | Director | 117,455 | — |
| — | Director | 109,737 | — |
| — | Director | 99,088 | — |
| — | Chief Financial Officer | 84,203 | — |
| — | Secretary, EVP, Gen. Counsel | 54,765 | — |
| — | Director | 54,748 | — |
| — | Chief Sci. & Med. Officer, EVP | 46,228 | — |
| — | Chief Operating Officer | 41,943 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BIAFW quote page; the site-wide leaderboard is on the insider transactions hub.